Diligence memo · auto-generated · as of July 3, 2026
BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
BriaCell Therapeutics Corp. operates in Pharmaceuticals, based in WEST VANCOUVER.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
BriaCell Therapeutics Corp. has raised $34M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $27M on 2021-06-03.
Most recent recorded round closed around 2021-06-03.
Valuation (modeled)modeled
Provath models BriaCell Therapeutics Corp. at approximately $642M (range $57M–$2.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.30× the median modeled value of Series B Pharmaceuticals companies in 2019–2021 (61 peers) — value vs value, same stage and era. Within the normal band (130% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 28 months.
Last raise 5.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 34.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 76% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 83% of those peers.
Closest niche peers: Evolus, Inc., HOOKIPA Pharma Inc., ESSA Pharma Inc., Pieris Pharmaceuticals, Inc., Amylyx Pharmaceuticals, Inc..
Peoplefiled
20 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.